Zhongtong Finance APP learned that Genscript Bio (01548) rose more than 4%. As of press time, it rose 4.29%, reported at HKD 9.50, and the turnover was HKD 89.9752 million.

On the news front, Legend Biotech has submitted Form 6-K to the US Securities and Exchange Commission, and announced for the first time the results of the phase 2 CARTITUDE-2 cohort D study for the treatment of patients with multiple myeloma. The data was orally reported at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and will be orally reported again at the 2024 European Hematology Association (EHA) Congress.

In addition, in early June, Genscript was asked to be investigated in the US. Genscript clarified in an announcement that the letter did not allege any illegal conduct by the company. The company will actively communicate with the committee and help them better understand the company's business.

It is understood that Genscript's revenue in the US market accounts for the majority of its performance. According to the 2023 annual report data, the company's sales revenue to customers in the United States, mainland China, Europe, the Asia-Pacific region (excluding mainland China), and other regions were approximately USD 506 million, USD 163 million, USD 99.5 million, USD 53.2 million, and USD 18.3 million, respectively, accounting for approximately 60.2%, 19.4%, 11.9%, 6.3%, and 2.2% of the company's total external revenue.